clock.bio Appoints BioNTech Veteran to Drive Rejuvenation Therapies
clock.bio, a company focused on rejuvenation biology, has announced the appointment of Dr. Michael Boehler as its new Chief Business Officer. Dr. Boehler brings extensive global commercial leadership experience from his tenure at BioNTech, where he played a pivotal role in the successful rollout of their mRNA vaccine. His expertise is expected to accelerate clock.bio’s platform development and advance therapies aimed at extending healthspan.
Key Takeaways
- Dr. Michael Boehler, formerly of BioNTech, joins clock.bio as Chief Business Officer.
- Boehler’s experience includes leading BioNTech’s global commercial scale-up and building strategic partnerships.
- clock.bio aims to translate its rejuvenation biology platform into therapies that extend human healthspan.
A New Leader for Rejuvenation Biology
Dr. Michael Boehler’s appointment marks a significant step for clock.bio as it seeks to commercialise its innovative rejuvenation biology platform. With over two decades of experience in the life sciences industry, Dr. Boehler has a proven track record in commercial strategy, general management, and business development. At BioNTech, he was instrumental in scaling the company into a global pharmaceutical leader, overseeing the commercial organisation and contributing to its successful initial public offering. His strategic insights were crucial to the widespread distribution of the COVID-19 vaccine.
Accelerating Healthspan Therapies
clock.bio is dedicated to developing therapies that reverse aging and extend healthspan. The company’s unique approach involves decoding the ‘rejuvenation genome’ and translating these discoveries into tangible interventions. Dr. Boehler expressed his enthusiasm for the company’s mission, stating, "Rejuvenation biology is one of the most exciting frontiers in medicine." He highlighted clock.bio’s "unique ability to decode the rejuvenation genome and turn those insights into meaningful interventions" as a key draw.
clock.bio’s Innovative Platform
The company’s proprietary platform is built on three core technologies designed for rapid discovery and validation of rejuvenation interventions:
- geneAge Atlas of Aging and Rejuvenation Genes: A genome-wide map identifying over 150 genetic targets.
- imAge: An AI-powered system for measuring biological age from single-cell images, facilitating high-throughput screening.
- clinAge Platform: A clinical engine for rapid human validation of rejuvenation therapies.
This integrated engine allows clock.bio to move efficiently from stem cell biology to human data, aiming to transform the science of aging into practical applications that enhance human healthspan. The company is initially focusing on topical and nutraceutical applications, providing a clear path to market while gathering crucial human data for future systemic therapies.
